Similar articles

• EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.

  Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Krause T, Mitterhauser M, Sonnenschein W, Bodei L, Delgado-Bolton RC, Gabriel M. Poeppel TD, et al. Eur J Nucl Med Mol Imaging. 2018 May;45(5):824-845. doi: 10.1007/s00259-017-3900-4. Epub 2017 Dec 12. Eur J Nucl Med Mol Imaging. 2018. PMID: 29234845
• Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models.

  Suominen MI, Fagerlund KM, Rissanen JP, Konkol YM, Morko JP, Peng Z, Alhoniemi EJ, Laine SK, Corey E, Mumberg D, Ziegelbauer K, Käkönen SM, Halleen JM, Vessella RL, Scholz A. Suominen MI, et al. Clin Cancer Res. 2017 Aug 1;23(15):4335-4346. doi: 10.1158/1078-0432.CCR-16-2955. Epub 2017 Mar 31. Clin Cancer Res. 2017. PMID: 28364014 Free PMC article.
• [Targeted radionuclide therapy for castration-resistant prostate cancer].

  Nakamura K, Ohga S, Sasaki T, Baba S, Honda H. Nakamura K, et al. Nihon Rinsho. 2014 Dec;72(12):2181-5. Nihon Rinsho. 2014. PMID: 25518355 Review. Japanese.
• Is There a Flare Phenomenon on Bone Scintigraphy in Men With Advanced Prostate Cancer Treated With Radium-223?

  Isensee G, Péporté A, Müller J, Schmid S, Gillessen S, Omlin A. Isensee G, et al. Clin Genitourin Cancer. 2018 Oct;16(5):349-354. doi: 10.1016/j.clgc.2018.04.002. Epub 2018 Apr 23. Clin Genitourin Cancer. 2018. PMID: 29778323
• Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.

  Vogelzang NJ. Vogelzang NJ. Expert Rev Clin Pharmacol. 2017 Aug;10(8):809-819. doi: 10.1080/17512433.2017.1345624. Epub 2017 Jul 3. Expert Rev Clin Pharmacol. 2017. PMID: 28649893 Review.